Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
Richard E Gilbert, Christian Mende, Ujjwala Vijapurkar, Sue Sha, Michael J Davies, Mehul Desai
Diabetes Therapy | SPRINGER HEIDELBERG | Published : 2017
This analysis was funded by Janssen Scientific Affairs, LLC, and was based on data from studies supported by Janssen Research & Development, LLC. Medical writing support, provided by Alaina Mitsch, PhD, of MedErgy, and article processing charges were funded by Janssen Global Services, LLC. Richard E. Gilbert is the Canada Research Chair in Diabetes Complications and this work was supported, in part, by the Canada Research Chairs Program. Richard E. Gilbert and Christian Mende contributed to the interpretation of data and the development of the manuscript. Ujjwala Vijapurkar and Michael J. Davies contributed to the analysis and interpretation of the data, and the development of the manuscript. Sue Sha and Mehul Desai contributed to the design and conduct of the original studies used in this pooled analysis; the acquisition, analysis, and interpretation of the data; and the development of the manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. These data were presented, in part, at the 76th Scientific Sessions of the American Diabetes Association on June 10-14, 2016 in New Orleans, Louisiana and at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) on September 12-16, 2016 in Munich, Germany. Canagliflozin has been developed by Janssen Research & Development, LLC, in collaboration with Mitsubishi Tanabe Pharma Corporation.